IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology | Conference

Dr. Bauer on Rovalpituzumab Tesirine in SCLC

October 4th 2016

Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine in the treatment of patients with small cell lung cancer in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Dr. Pennell on Unique Treatment-Related Toxicities in Lung Cancer

October 1st 2016

Nathan Pennell, MD, PhD, medical oncologist, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the rare toxicities seen in patients with lung cancer.

Dr. Powell on Important Future Directions in Lung Cancer

September 29th 2016

Charles Powell, MD, director, Mount Sinai-National Jewish Health Respiratory Institute, sheds light on what he feels oncologists should be tackling in the future of treating patients with lung cancer.

Early Activity Observed With Capmatinib in Advanced NSCLC

September 28th 2016

The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate of 20% when administered to patients with advanced c-MET–dysregulated non–small cell lung cancer.

Dr. Neal on Exciting Advancements in the Field of Lung Cancer

September 28th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses exciting advancements in the field of lung cancer over the past few years.

Dr. Gaspar on a Physician Survey on Prophylactic Cranial Irradiation in SCLC

September 28th 2016

Laurie E. Gaspar, MD, professor, Radiation Oncology, University of Colorado Denver, discusses a survey she conducted for physicians on the use of prophylactic cranial irradiation for patients with limited small cell lung cancer.

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLC

September 24th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses updated efficacy findings from the BIRCH trial, which was a phase II study of atezolizumab (Tecentriq) for patients with PD-L1–selected advanced non–small cell lung cancer (NSCLC). Wakelee discussed these findings during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Hirsch on Value of PD-L1 Testing in Patients With Lung Cancer

September 23rd 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer (IASLC), discusses the value of PD-L1 assays for patients with non–small cell lung cancer. Hirsch shared his during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care

September 23rd 2016

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.